Filing Overview
Registrant: Flora Growth Corp., a Canadian foreign private issuer filing on Form 6-K under Form 20-F. The filing is for August 2021 and was signed on August 12, 2021. The provided request metadata identifies Zerostack Corp., but the filing names Flora Growth Corp.; this entity discrepancy should be verified.
Business Context and Reporting Period
This filing reports changes to Flora Growth Corp.’s board of directors and furnishes related exhibits, including a resignation letter and an August 12, 2021 press release. It is not a financial-results filing.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating metrics, or other financial figures.
Material Changes
- Stan Bharti resigned as a director effective August 5, 2021.
- Effective August 12, 2021, the board appointed Dr. Annabelle Manalo-Morgan to fill the vacancy.
- Dr. Manalo-Morgan will serve until the next annual meeting and until her successor is elected and qualified, subject to earlier departure.
Governance, Outlook, and Risks
- Dr. Manalo-Morgan is described as an independent director under applicable SEC and Nasdaq rules.
- She is the founder and CEO of Manalo Holdings, LLC, founder and chief scientific officer of Masaya Medical, and a scientific advisor to Medolife, Inc. She previously served as chief scientific officer of Tikun Olam.
- The company disclosed no arrangements or understandings relating to her appointment, no family relationships with company directors or officers, and no reportable related-party transaction under Item 404(a) of Regulation S-K.
- She is expected to participate in the company’s standard director compensation arrangements.
- The filing provides no financial guidance, operating outlook, contingencies, or specific risk-factor updates.
Investor Verification Items
- Verify the correct registrant, because the request metadata says Zerostack Corp. while the filing identifies Flora Growth Corp.
- Review Exhibits 99.1 and 99.2 for the complete resignation letter and appointment press release.
- Confirm the board’s post-appointment composition and Dr. Manalo-Morgan’s independence and compensation arrangements in subsequent filings.
- Consult the company’s financial filings separately for financial performance, liquidity, debt, and outlook information.